Table 3 Median pharmacokinetic... | American Society of Hematology

Table 3

Median pharmacokinetic parameters for lumiliximab and rituximab for patients who received 500 mg/m² of lumiliximab

Drug	Cycle	n*	C_max, μg/mL	AUC_inf, μg/day/mL	CL, mL/day	V, L	t_1/2, day
Lumiliximab	1	19	183	451	2252	4.50	2.1
Lumiliximab	3	12	217	1494	677	6.00	6.5
Lumiliximab	6	8	345	3760	295	6.60	18.1
Rituximab	1	19	136	402	1742	9.71	5.3
Rituximab	3	12	243	1758	578	8.32	10.0
Rituximab	6	8	269	3611	263	9.69	27.2

Drug	Cycle	n*	C_max, μg/mL	AUC_inf, μg/day/mL	CL, mL/day	V, L	t_1/2, day
Lumiliximab	1	19	183	451	2252	4.50	2.1
Lumiliximab	3	12	217	1494	677	6.00	6.5
Lumiliximab	6	8	345	3760	295	6.60	18.1
Rituximab	1	19	136	402	1742	9.71	5.3
Rituximab	3	12	243	1758	578	8.32	10.0
Rituximab	6	8	269	3611	263	9.69	27.2

The absolute patient number for individual assessments may vary.